Aaron Seo (@ASeoMDPhD) profile picture

Rad Onc @queenshealthhi | alumnus @MDAndersonNews, @UW_MSTP, @UTAustin | Tweets=my own

Joined March 2020
Photo by Aaron Seo (@ASeoMDPhD)Photo by Aaron Seo (@ASeoMDPhD)Photo by Aaron Seo (@ASeoMDPhD)Photo by Aaron Seo (@ASeoMDPhD)Photo by Aaron Seo (@ASeoMDPhD)
Helpful #NasopharynxCancer review now available in @RedJournal! #RadOnc #NPC #hncsm The latest on: 🔹 Treatment de-intensification 🔹 Immunotherapy intensification 🔹 Personalizing care with EBV DNA 🔹 Strategies for recurrent/metastatic disease Free access: authors.elsevier.com/c/1mPlt… Includes great figures summarizing 2024/2025 consensus guidelines for primary and nodal radiation oncology target volume delineation. 👇
1
33
73
5,239
Dr. Ethan Ludmir @ebludmir is brilliant, humble & so quietly impressive. Loved getting to chat with him about many topics – oligometastatic pancreas ca, Bayesian statistics, career advice & more. Full video link below. Watch if you want to become inspired about GI onc/rad onc!
3
15
1
85
7,305
Celebrity alert: Troy is an MD Anderson #radonc resident and the lead author of the updated Revised STARS study reported at #ASTRO25 with a median f/u time of 10y showing no measurable benefit of surgery for stage IA NSCLC. cc @JoeChangMD
Thank you @daniel_hamstra, @MFlanaganMD, and the rest of the Baylor Rad Onc team for letting me crash your happy hour yesterday with Visiting Professor @DrewMoghanaki. Always fun meeting a living legend!
3
19
66
7,212
Passed the Rad Onc Oral Boards! My amazing team gave me a wonderful surprise this morning. I am truly blessed with such wonderful coworkers. Time to eat cake for breakfast!
1
1
58
1,605
Aaron Seo retweeted
Radiation oncology is facing a serious payment crisis, and today, nearly 100 #RadOncs are on Capitol Hill pushing for change. They’re advocating for Medicare payment reform, fixing a broken #priorauth system, and stronger federal investment in radiation research. Join them in advocating by using ASTRO's convenient grassroots tool. #ASTROAdvocacy Advocate for your field: ow.ly/jnca50YR5Y0
9
15
1,186
Aaron Seo retweeted
Replying to @Jdcramer
@Jdcramer has made a critical point below about KEYNOTE-689. The EFS rules in KN-689 require careful review to interpret these results.  A protocol-specific event was determined by blind independent central review (BICR), but if growth in the pre-surgical CT was perceived to be a “flare” (i.e. potential progression), surgery was supposed to proceed unless unresectable (protocol quote below). In order to be considered an event, repeat imaging was required 4-8 weeks later, and obviously if the tumor was still resectable the patient would go to surgery before then. This definition means it was extremely difficult to have an event before surgery, even if the tumor grew and the surgery was more extensive than initially anticipated. Thus some patients may have been harmed by neoadjuvant treatment, but we would not see that in the event data. Thus there is this important disconnect: 82 patients in the pembro arm stopped the drug due to progression (by the investigator, as shown in the CONSORT diagram), even though there were only 69 progression events (by BICR, used for endpoint analyses). Is perioperative immunotherapy doing something favorable and important in a subset of these patients? Yes, and hopefully we can refine its use to the right population and with the right regimen (adding neoadjuvant chemo or RT?). Is it distinctly possible/probable that some patients are progressing on neoadjuvant pembro, leading to a worse outcome in some domain, but we cannot see that in these data? Yes, unfortunately, also true.
Question for those who’ve dug into KEYNOTE-689: If 43 pts had early ‘clinical progression’ (Table S2B), why isn’t there an early drop in EFS with neoadjuvant pembro? How do you reconcile this?
3
11
1
28
7,824
Aaron Seo retweeted
The linked paper is a nice document and summary product, but let's emphasize a few highlights: 1. Statement 16, strong consensus: ctHPVDNA should supplement conventional surveillance tools, rather than reducing or replacing them. Natural corollary: if it is not reducing or replacing surveillance, what is the point? 2. Statement 9, strong consensus: Detectable ctHPVDNA without clinical or radiographic evidence of disease often increases patient distress. 3. Statement 5, strong consensus: Large-scale, prospective randomized controlled trials are necessary to validate ctHPVDNA's role in HPV+ oropharyngeal cancer management. I would change that statement from validate to determine. Validate assumes it has a role today, but as the document states, it doesn't reduce or replace any currently established surveillance tools. There are so many exciting ways that ctHPVDNA may influence care (screening/diagnosis, de-escalation, non-imaging-based surveillance) but these strategies need to be established in prospective randomized trials.
The California Head & Neck Consortium released the first multidisciplinary consensus recommendations on the use of circulating tumor HPV DNA in HPV+ oropharyngeal carcinoma. The panel of 33 experts representing 15 institutions reached strong consensus that a tool like the NavDx® test should be incorporated into routine surveillance. The consensus recommendations also included: Using an option like the NavDx test improves time to recurrence detection vs. conventional surveillance tools, but should supplement these methods, not reduce or replace them. The recommended time for a patient’s first post-treatment test is 3 months. Serial testing should be performed in conjunction with conventional surveillance every 3 months in the first 2 years post-treatment and every 6 months in years 3-5. For patients with a single positive post-treatment test where no clinical or radiographic evidence of disease is present, the best time to repeat the test is in one month. Earlier molecular detection of locoregional or oligometastatic disease should improve outcomes. These recommendations reinforce real-world clinical validation and value of new technologies like the NavDx test in earlier detection of molecular residual disease and recurrence of HPV+ oropharyngeal cancer. Access the full publication here: bit.ly/3MrPgeG  #ctHPVDNA #HeadAndNeckCancer #Oncology #MRD #NavDx #CancerSurveillance #hncancer
5
5
1
17
4,937
January is #cervicalcancerawarenessmonth. #brachytherapy remains a powerful, targeted treatment option that helps improve outcomes & preserve quality of life for patients. Together, we raise awareness, advance care, & support those impacted. #thisisbrachytherapy #cancerawareness
5
1
8
1,202
Our new editorial is live! 📢 PFS & OS undervalue SABR in oligoprogression trials. Focus on TTF, TTNT, and QoL instead—highlighting SABR as a repeatable strategic ally to systemic therapy. 👉 authors.elsevier.com/a/1mL-p…
6
58
1
130
7,914
I do 0.5gy x 6 fractions. I reassess in 3 months. If partial response, I offer a 2nd course. About 60-70% of patients will need a 2nd course. Overall 80-85% response rates in the literature and in my own personal experience
1
2
11
1,038
Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2
In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team. @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden ow.ly/yCUo50XgSQh
2
38
236
38,729
Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇 bit.ly/BestOfASTRO25
1
32
4
77
17,221
❗️ As VALOR accrues, what is the existing data from STARS ROSEL that SBRT is non-inferior to lobectomy? Using beta moment matching and sampling from this, assuming 5% NI margin, my bet is on SBRT #numpy #matplotlib
455/670 pts have been enrolled in phase III randomized study comparing SABR vs surgery in early-stage NSCLC with 2.5 Y median F/U. Complete enrollment is anticipated in 2027. #wclc2025 I still remember I participated NCI advisory committee meeting and fought for #VALOR in 2015.
1
7
1
21
3,396
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics authors.elsevier.com/a/1ljMf…
19
72
11
200
25,546
The best mentor a resident could ask for. Mahalo, @ChadTangMD!
Congrats to the @MDAndersonNews radiation oncology class of 2025. Honored to get the James Cox mentoring award. Thanks @AlexSherryMD and Aaron Seo for being amazing mentees.
1
1
9
889
Metastasis-directed radiation therapy can help patients with oligometastatic clear cell renal cell carcinoma avoid systemic therapies without compromising outcomes, findings shared by our Dr. Chad Tang at #AACR25 show. More: brnw.ch/21wSeae @AACR @ChadTangMD #EndCancer
8
13
3
62
9,272
#RadOnc Heme High-Yield Oral Boards: 2025 Update! Some key slides highlighted below. Feedback or commentary is welcome. Good luck everyone! docs.google.com/presentation…
I put together a few high-yield slides for #RadOnc oral boards RT-friendly regimens for HL and NHL. 📌 For HL, there is a focus on GHSG staging for a simplified decision tree. 📌 Goal: Not comprehensive. Comments and feedback are welcomed! Enjoy 😃 https://teapawt.net/t.co/aetFgIVhl3
3
15
66
9,610
If you want to get started with benign #RadOnc, the best first thing to do in my opinion is educate your colleagues. LDRT is a standard of care therapy, it is covered by insurance, and there are decades of evidence to support its efficacy.
1
3
29
1,788